<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-163616</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Radiation maculopathy treated with intravitreal bevacizumab</dc:title>
<dc:description xml:lang="en">Case report:: A 47 year-old woman with a choroidal melanoma developed a macular oedema secondary to radiation therapy 75 months after brachytherapy plaque. The patient received 3 intravitreal Bevacizumab injections. Discussion: The patient had a good response to bevacizumab treatment. In fact, there was a reduction in the macular oedema measured by optical coherence tomography (OCT) scan, as well as an improvement in best corrected visual acuity. There was no recurrence of macular oedema, and visual acuity remained stable after 3-years follow-up (AU)</dc:description>
<dc:creator>Galván-Carrasco, MP</dc:creator>
<dc:creator>Sánchez-Vicente, JL</dc:creator>
<dc:creator>Vital-Berral, C</dc:creator>
<dc:creator>Alfaro-Juárez, A</dc:creator>
<dc:creator>Rueda-Rueda, T</dc:creator>
<dc:creator>Muñoz-Morales, A</dc:creator>
<dc:creator>Castilla-Lázpita, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Paciente con un melanoma coroideo que desarrolló un edema macular secundario a maculopatía por radiación a los 75 meses del tratamiento con braquiterapia. La enferma recibió 3 inyecciones intravítreas de bevacizumab. Discusión: La respuesta al tratamiento con bevacizumab fue favorable, con disminución del edema macular observable en la tomografía de coherencia óptica y mejoría de la agudeza visual. No se produjeron recurrencias del edema macular, y la agudeza visual permaneció estable durante un periodo de seguimiento de 3 años (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;92(6): 283-286, jun. 2017. ilus</dc:source>
<dc:identifier>ibc-163616</dc:identifier>
<dc:title xml:lang="es">Bevacizumab intravítreo en el tratamiento de la maculopatía por radiación</dc:title>
<dc:subject>^d55974^s22079</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d54215^s22074</dc:subject>
<dc:subject>^d1944^s22020</dc:subject>
<dc:subject>^d8714^s22059</dc:subject>
<dc:subject>^d12271^s22057</dc:subject>
<dc:subject>^d28269^s22059</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d28131^s22057</dc:subject>
<dc:subject>^d28131^s22027</dc:subject>
<dc:type>article</dc:type>
<dc:date>201706</dc:date>
</metadata>
</record>
</ibecs-document>
